Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Lab Invest. 2008 Aug 11;88(10):1121–1129. doi: 10.1038/labinvest.2008.69

Table 1.

LPS-induced changes in hepatic metabolite, gene expression, and enzyme activity

6 h after LPS 18 h after LPS

% of control value % of control value
GSH (μmol/gm) 60 ± 3* 49 ± 8.4*
mRNA levels
 MAT1A 155 ± 13** 242 ± 30
 MAT2A 181 ± 19** 420 ± 40*
 GNMT 48 ± 7* 35 ± 6*
 GCLC 52 ± 5** 38 ± 4
 GCLM 38 ± 5* 34 ± 4*
 GS 62 ± 10** 55 ± 4
 iNOS 22941 ± 9005** 6057 ± 1029*
 IL-10 2189 ± 486 3234 ± 693*
 IL-1β 1892 ± 348 262 ± 17
Enzyme activity
 MATI/III 53.5 ± 3.2* 58 ± 11**

Abbreviations: GCLC, glutamate-cysteine ligase catalytic; GCLM, glutamatecysteine ligase catalytic and modifier subunit; GNMT, glycine N-methyltransferase; GS, glutathione synthetase; GSH, glutathione; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MAT, methionine adenosyltransferase.

Results are mean ± s.e. from 5 to 12 determinations for each group. Hepatic GSH levels, mRNA levels, and MATI/III activity were measured as described in ‘Materials and Methods’ 6 and 18 h following LPS administration and expressed as % of control values.

*

P < 0.001,

**

P < 0.05,

P < 0.01 vs control.